Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies

Leukemia & Lymphoma
W L ZhaoZ Y Wang

Abstract

Arsenic trioxide (As2O3) has recently been identified as an effective drug in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia (APL) without cross-resistance to all-trans retinoic acid and achieved complete remission rates of 80-90% according to most reports. With intravenous infusion at a dose of 0.08-0.16 mg/kg daily, a course of 28-42 days is required to induce remission. As2O3 in combination with chemotherapy as postremission therapy results in longer survival than arsenic alone. In vitro, As2O3 exerts dose-dependent dual effect; triggering apoptosis at relatively high concentration (0.5-2.0 micromol/l), which is associated with the disruption of mitochondrial transmembrane potentials, while inducing partial differentiation at low concentration (0.1-0.5 micromol/l), which might be related to retinoic acid signaling pathway. Importantly, at both concentrations, As2O3 can degrade PML (promyelocytic leukemia) -RAR alpha (retinoic acid receptor), an oncoprotein that has a central role in leukemogenesis.

Citations

Feb 23, 2007·Science in China. Series C, Life Sciences·Jin ZhouBaofeng Yang
Dec 4, 2003·Mutation Research·Jia-Ran GurrKun-Yan Jan
Dec 31, 2002·Adverse Drug Reactions and Toxicological Reviews·Maciej J BoguszHuda Hassan
Dec 29, 2004·Leukemia & Lymphoma·Markus Thomas RojewskiHubert Schrezenmeier
Oct 30, 2004·Leukemia & Lymphoma·Suman KambhampatiLeonidas C Platanias
Dec 3, 2014·International Journal of Cardiology·Wenya MaBenzhi Cai
Jan 24, 2012·Journal of Ethnopharmacology·Shengpeng WangYitao Wang
Sep 10, 2020·Drug Development and Industrial Pharmacy·Xiao LiuYanyan Jiang
Jul 25, 2003·Expert Opinion on Pharmacotherapy·Simrit Parmar, Martin S Tallman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

© 2022 Meta ULC. All rights reserved